- Market Capitalization, $K 656,862
- Shares Outstanding, K 97,169
- Annual Sales, $ 40 K
- Annual Income, $ -170,060 K
- 60-Month Beta 1.75
- Price/Sales 14,507.56
- Price/Cash Flow N/A
- Price/Book 4.65
|Period||Period Low||Period High||Performance|
| || |
-0.89 (-11.63%)since 08/30/22
| || |
+2.14 (+46.32%)since 06/30/22
| || |
-2.67 (-28.31%)since 09/30/21
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...
Approaching full enrollment in UPLIFT clinical trial; initiated patient screening in UP-NEXT clinical trialCleared INDs for XMT-1660 and XMT-2056Enhanced...
GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase feeIf GSK exercises its option, Mersana...
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on...
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on...
The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...